ResMed Inc

ResMed insider sale: 2,000 shares sold at $260.22 on March 4, 2026 – a routine, rule‑based liquidity move that won’t sway the stock, with the company’s solid fundamentals and sleep‑care growth outlook intact.

ResMed CFO Brett Sandercock sells 1,000 shares at $257.03, a minimal dip to 0.01%—insider trading reveals steady confidence in ResMed’s sleep‑disorder device business and long‑term strategy.